Tiffany F Kautz
Overview
Explore the profile of Tiffany F Kautz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson T, Orr M, Orr T, Rohde S, Ehrenberg A, Thorn E, et al.
Alzheimers Dement
. 2024 Dec;
21(2):e14487.
PMID: 39737785
Introduction: Alzheimer's disease (AD), primary age-related tauopathy (PART), and chronic traumatic encephalopathy (CTE) all feature hyperphosphorylated tau (p-tau)-immunoreactive neurofibrillary degeneration, but differ in neuroanatomical distribution and progression of neurofibrillary degeneration...
2.
Wadop Y, Vasquez E, Mathews J, Muhammad J, Mavarez R, Satizabal C, et al.
bioRxiv
. 2024 Aug;
PMID: 39211240
Alzheimer's disease and related dementias (ADRD) have been associated with alterations in both oral and gut microbiomes. While extensive research has focused on the role of gut dysbiosis in ADRD,...
3.
Charisis S, Short M, Bernal R, Kautz T, Trevino H, Mathews J, et al.
Alzheimers Dement
. 2024 Aug;
20(9):5849-5860.
PMID: 39132759
Introduction: We investigated the associations of leptin markers with cognitive function and magnetic resonance imaging (MRI) measures of brain atrophy and vascular injury in healthy middle-aged adults. Methods: We included...
4.
Garbarino V, Palavicini J, Melendez J, Barthelemy N, He Y, Kautz T, et al.
Res Sq
. 2024 Mar;
PMID: 38496619
Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer's disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures....
5.
Walker J, Orr M, Orr T, Thorn E, Christie T, Yokoda R, et al.
Alzheimers Dement
. 2023 Oct;
20(2):783-797.
PMID: 37777848
Introduction: Alzheimer's disease (AD) and primary age-related tauopathy (PART) both harbor 3R/4R hyperphosphorylated-tau (p-tau)-positive neurofibrillary tangles (NFTs) but differ in the spatial p-tau development in the hippocampus. Methods: Using Nanostring...
6.
Gonzales M, Garbarino V, Kautz T, Palavicini J, Lopez-Cruzan M, Dehkordi S, et al.
Nat Med
. 2023 Sep;
29(10):2481-2488.
PMID: 37679434
Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label, proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and quercetin (Q), was conducted in early-stage symptomatic...
7.
Fongang B, Satizabal C, Kautz T, Wadop Y, Muhammad J, Vasquez E, et al.
Sci Rep
. 2023 Aug;
13(1):13622.
PMID: 37604954
A bidirectional communication exists between the brain and the gut, in which the gut microbiota influences cognitive function and vice-versa. Gut dysbiosis has been linked to several diseases, including Alzheimer's...
8.
Gonzales M, Wiedner C, Wang C, Liu Q, Bis J, Li Z, et al.
Ann Clin Transl Neurol
. 2022 Sep;
9(10):1574-1585.
PMID: 36056631
Objective: Expression of glial fibrillary acidic protein (GFAP), a marker of reactive astrocytosis, colocalizes with neuropathology in the brain. Blood levels of GFAP have been associated with cognitive decline and...
9.
Sarnowski C, Ghanbari M, Bis J, Logue M, Fornage M, Mishra A, et al.
Commun Biol
. 2022 Apr;
5(1):336.
PMID: 35396452
Circulating total-tau levels can be used as an endophenotype to identify genetic risk factors for tauopathies and related neurological disorders. Here, we confirmed and better characterized the association of the...
10.
Haines C, Campos R, Azar S, Warmbrod K, Kautz T, Forrester N, et al.
Zoonoses (Burlingt)
. 2022 Mar;
2.
PMID: 35262074
Background: Venezuelan equine encephalitis virus (VEEV) is an arbovirus endemic to the Americas. There are no approved vaccines or antivirals. TC-83 and V3526 are the best-characterized vaccine candidates for VEEV....